Aubrey Trevelin Sprabery

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

Vinod Chandran, Désirée van der Heijde, Roy Fleischmann et al. · Lara D. Veeken · 2020 · 54 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +12

Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study

Josef S Smolen, Anthony Sebba, Eric Ruderman et al. · Rheumatology and Therapy · 2020 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire

William Tillett, Chen‐Yen Lin, Art Zbrozek et al. · Rheumatology and Therapy · 2019 · 43 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure

Atul Deodhar, Bernard Combe, Ana P. Accioly et al. · Annals of the Rheumatic Diseases · 2022 · 21 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

Bernard Combe, Tsen‐Fang Tsai, J. Eugene Huffstutter et al. · Arthritis Research & Therapy · 2021 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12